MIRXES-B(02629)发布公告，于2026年1月29日(交易时段前)，公司与配售代理订立配售协议，据此， 公司已同意委聘配售代理，而配售代理已个别(并非共同亦非共同及个别)同意担任公司的代理，尽最大 努力促使承配人根据配售协议所载条款并受其条件所限按配售价每股配售股份32.50港元认购合共2188.8 万股新股份。配售价为每股配售股份32.50港元，较股份于2026年1月28日(即紧接配售协议日期前最后 一个交易日)在香港联交所所报收市价每股股份36.88港元折让约11.88%。 假设所有配售股份获悉数认购，预期配售事项的所得款项总额合共将约为7.11亿港元。配售事项的所得 款项净额，预期将约为6.73亿港元(按每股配售股份净价格将约为30.77港元的基准)。 配售股份的数目占：(a)本公告日期已发行现有股份总数约7.92%;及(b)已发行股份总数约7.34%，经紧随 交割后发行配售股份扩大(假设所有配售股份获悉数认购，且除公司发行配售股份外，由本公告日期起 至交割期间已发行股份总数概无变动)。 ...

配售股份的数目占：(a)本公告日期已发行现有股份总数约7.92%;及(b)已发行股份总数约7.34%，经紧随 交割后发行配售股份扩大(假设所有配售股份获悉数认购，且除公司发行配售股份外，由本公告日期起 至交割期间已发行股份总数概无变动)。 假设所有配售股份获悉数认购，预期配售事项的所得款项总额合共将约为7.11亿港元。配售事项的所得 款项净额，预期将约为6.73亿港元(按每股配售股份净价格将约为30.77港元的基准)。 智通财经APP讯，MIRXES-B(02629)发布公告，于2026年1月29日(交易时段前)，公司与配售代理订立配 售协议，据此，公司已同意委聘配售代理，而配售代理已个别(并非共同亦非共同及个别)同意担任公司 的代理，尽最大努力促使承配人根据配售协议所载条款并受其条件所限按配售价每股配售股份32.50港 元认购合共2188.8万股新股份。配售价为每股配售股份32.50港元，较股份于2026年1月28日(即紧接配售 协议日期前最后一个交易日)在香港联交所所报收市价每股股份36.88港元折让约11.88%。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司（「香港聯交所」）對本公告的內容概 不負責，對其準確性或完整性亦不發表任何聲明，並明確表示不會就因本公告全部或任何部 分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 本公告或其任何副本概不得直接或間接在美國，或在發佈或派發本公告屬違法的任何其他司 法權區發佈或派發。 本公告僅作參考用途，並不構成收購、購買或認購本公司任何證券的邀請或要約。 本公告並非亦不構成在美國（定義見1933年美國證券法（「證券法」）S規例）銷售證券的要約或 邀請的一部分。本公告或其任何內容或其任何副本不得攜進美國境內或於美國境內或在任何 進行有關發佈或派發可能屬違法的任何司法權區直接或間接派發。除非本公告所指證券根據 證券法登記或獲豁免遵守證券法的登記規定，否則有關證券未曾亦不會根據證券法登記，且 不得在美國境內提呈發售、出售或以其他方式轉讓。本公司無意在美國登記本公告所述任何 證券或在美國公開發售任何證券。 Mirxes Holding Company Limited （ 於 開 曼 群 島 註 冊 成 立 的 有 限 責 任 公 司 ） （股份代號：2629） 根據一般授權 ...

Group 1 - The core point of the news highlights the top short-selling ratios and amounts for various companies, indicating significant market sentiment towards these stocks [1][2]. - AIA Group Limited (友邦保险-R) and Anta Sports Products Limited (安踏体育-R) both have a short-selling ratio of 100.00%, indicating a high level of bearish sentiment [1][2]. - The top three companies by short-selling amount are Alibaba Group Holding Limited (阿里巴巴-W) with 4.031 billion, Tencent Holdings Limited (腾讯控股) with 2.553 billion, and Alibaba Health Information Technology Limited (阿里健康) with 1.776 billion [1][2]. Group 2 - The top short-selling ratio rankings show that AIA Group Limited (友邦保险-R) leads with a short-selling amount of 1.9534 million and a ratio of 100.00% [2]. - JD.com, Inc. (京东集团-SWR) has a short-selling ratio of 99.19% with a short-selling amount of 0.6316 million, indicating strong market pressure [2]. - The deviation values indicate that JD.com (京东集团-SWR) has the highest deviation at 44.47%, suggesting significant divergence from its historical short-selling average [2].

Market Overview - The Hong Kong stock market opened higher on January 12, with the Hang Seng Index rising by 0.55% to 26,376.84 points, the Hang Seng Tech Index increasing by 0.88% to 5,737.43 points, the National Enterprises Index up by 0.75% to 9,116.01 points, and the Red Chip Index gaining 0.68% to 4,129.13 points [1] Company News - Sunny Optical Technology (02382.HK) reported a December smartphone lens shipment of 95.592 million units, a year-on-year decrease of 8.9%. The automotive lens shipment was 7.477 million units, a year-on-year increase of 17.7%. Smartphone camera module shipments were 37.744 million units, down 29.3% year-on-year, primarily due to customer inventory control and holiday factors [2] - Orient Overseas International (00316.HK) reported a 17.2% year-on-year decrease in fourth-quarter shipping revenue to USD 2.081 billion. Total cargo volume increased by 0.8%, and capacity rose by 4.5%. The overall load factor decreased by 3.1% compared to the same period in 2024, with average revenue per standard container down 17.8% year-on-year [2] - China Jinmao (00817.HK) achieved a cumulative contracted sales amount of RMB 113.5 billion for 2025, representing a year-on-year increase of 15.52% [3] - R&F Properties (02777.HK) reported total sales revenue of approximately RMB 14.21 billion for 2025, a year-on-year increase of 26.54% [4] - Zhongliang Holdings (02772.HK) reported a cumulative contracted sales amount of approximately RMB 12.07 billion for 2025, a year-on-year decrease of 32.68% [5] - Greenland Hong Kong (00337.HK) reported contracted sales of approximately RMB 7.214 billion for 2025, a year-on-year decrease of 21.66% [6] - Longyuan Power (00916.HK) completed a cumulative power generation of 76.4694 million MWh for 2025, a year-on-year increase of 1.22% [7] - Dekang Agriculture and Animal Husbandry (02419.HK) reported sales of 1.1097 million pigs in December, generating revenue of RMB 1.664 billion [8] - COFCO Joycome (01610.HK) reported a December pig output of 567,000 heads, a month-on-month increase of 1.43% [9] - Hengding Industrial (01393.HK) reported a coal production of 5.415 million tons for 2025, a year-on-year increase of 31% [10] Industry Insights - Dongwu Securities suggests that the Hong Kong stock market is entering a period of oscillation and upward movement, emphasizing the importance of dividends as a base and the potential for technology growth in the first half of the year [15] - CITIC Construction Investment highlights the strong performance of copper and aluminum in the recent market, indicating that copper prices are expected to continue rising, with a target of USD 13,000 not being the peak for this cycle [15] - Zhongtai Securities notes that China's rare earths have become a crucial strategic component in the global high-tech industry chain amid increasing Sino-US tech competition, recommending focus on resource companies with high concentration and barriers [16]

Core Insights - The company has established a strategic partnership with N Health and Bangkok Dusit Medical Services (BDMS) to introduce advanced microRNA cancer screening solutions in Thailand, marking a significant step forward in early cancer detection and patient outcomes in the region [1][2] Market Overview - The Thai health check market is experiencing substantial growth, projected to reach approximately $500 million by 2030, with a compound annual growth rate (CAGR) of 9.2% starting from 2025. The specialty health check segment is the fastest-growing part, indicating strong demand for advanced and targeted screening solutions [1] Strategic Partnership - The partnership will leverage the company's cutting-edge miRNA technology and innovative screening solutions, such as GASTROClear™ for gastric cancer and LUNGClear™ for lung cancer, to enhance early disease detection services across nearly 60 hospitals within the N Health network [2] Product Launch - The company plans to launch new home screening test kits, HELICORapid for H. pylori detection and FITRapid for fecal occult blood detection, in Thailand starting January 9, 2026, following approvals from the Thai FDA [3] Innovation in Testing - The new home test kits are the first of their kind in the Thai market, featuring an innovative single-device design that integrates sample collection and testing into one component, significantly reducing contamination and user error risks [3][4] Accessibility and Consumer Focus - The company aims to distribute these test kits through modern trade channels and pharmacies across Thailand, aligning with evolving consumer healthcare behaviors and the increasing demand for preventive, self-diagnostic solutions [4]

Core Insights - The company has established a strategic partnership with N Health and Bangkok Dusit Medical Services to introduce advanced microRNA cancer screening solutions in Thailand, marking a significant step forward in early cancer detection and patient outcomes in the region [1][2] Group 1: Strategic Partnership and Market Growth - The partnership aims to penetrate the rapidly growing health check market in Thailand, which is expected to reach approximately $500 million by 2030, with a compound annual growth rate (CAGR) of 9.2% starting from 2025 [1] - The specialized health check segment is the fastest-growing part of the market, indicating strong demand for advanced and targeted screening solutions [1] Group 2: Cancer Screening Solutions - The partnership will leverage the company's cutting-edge miRNA technology and innovative screening solutions, such as GASTROClear for gastric cancer and LUNGClear for lung cancer, to improve cancer treatment standards in the region [2] - Nearly 60 hospitals within the N Health network will adopt the cancer screening tests, supporting broader access to early disease detection services across Thailand and Southeast Asia [2] Group 3: Home Testing Kits Launch - The company announced the launch of new home screening test kits, HELICORapid for H. pylori detection and FITRapid for fecal occult blood detection, in Thailand, following approvals from the Thai FDA [3] - These home test kits are the first of their kind in the Thai market, designed to integrate sample collection and testing into a single, user-friendly device, significantly reducing contamination and user error risks [3][4] Group 4: Accessibility and Consumer Engagement - The home test kits will be distributed through modern trade channels and pharmacies across Thailand, catering to evolving consumer healthcare behaviors and the increasing demand for preventive, self-diagnostic solutions [4] - The launch emphasizes the company's mission to democratize early detection, empowering individuals with practical tools to manage their health and support the healthcare system through early intervention and increased disease awareness [4]

Core Viewpoint - The strategic partnership between MIRXES-B and N Health aims to introduce advanced microRNA cancer screening solutions in Thailand, marking a significant step forward in early cancer detection and improving patient outcomes in the region [1][2]. Group 1: Strategic Partnership - The partnership is established to leverage MIRXES-B's cutting-edge miRNA technology and innovative screening solutions, such as GASTROClear™ for gastric cancer and LUNGClear™ for lung cancer [2]. - The collaboration will introduce cancer screening tests across nearly 60 hospitals within the N Health network, supporting broader access to early disease detection services in Thailand and Southeast Asia [2]. - N Health aims to enhance its role in providing end-to-end healthcare solutions and expand the accessibility of advanced cancer screening nationwide, integrating cancer risk assessments into preventive care [2]. Group 2: Market Potential - Thailand's health check-up market is projected to reach approximately $500 million by 2030, with a compound annual growth rate (CAGR) of 9.2% starting from 2025, indicating strong demand for advanced and targeted screening solutions [1]. - The increasing awareness of preventive healthcare and rising chronic disease prevalence create an ideal environment for adopting innovative diagnostic technologies like MIRXES-B's miRNA tests [1]. Group 3: New Product Launch - The company plans to launch new home screening test kits, HELICORapid for H. pylori detection and FITRapid for fecal occult blood detection, in Thailand starting January 9, 2026, following approvals from the Thai FDA [3]. - These home test kits are designed to complement the core miRNA cancer screening solutions and are the first of their kind in the Thai market, featuring an innovative single-device design that minimizes processing steps and reduces contamination risks [3][4]. - The distribution of these test kits will be through modern trade and pharmacy channels across Thailand, aligning with evolving consumer healthcare behaviors and increasing demand for preventive, self-diagnostic solutions [4].

Group 1 - MIRXES-B has established a strategic partnership with N Health to introduce advanced microRNA cancer screening solutions in Thailand, marking a significant step in early cancer detection and improving patient outcomes in the region [1] - The Thai health check market is experiencing substantial growth, projected to reach approximately $500 million by 2030, with a compound annual growth rate of 9.2% starting from 2025, indicating strong demand for advanced and targeted screening solutions [1] - The partnership aims to leverage the increasing awareness of preventive healthcare and the rising prevalence of chronic diseases to create an ideal environment for adopting innovative diagnostic technologies like miRNA testing [1] Group 2 - The company launched a new series of home screening test kits in Thailand, including HELICORapid for detecting H. pylori infections and FITRapid for detecting fecal occult blood, both of which are significant cancer risk factors [2] - These home testing kits are the first of their kind in the Thai market, featuring an innovative single-device design that integrates sample collection and testing into a streamlined component, reducing processing steps and minimizing contamination risks [2] - The company aims to expand its sales and marketing efforts into the consumer sector, providing easy-to-use and hygienic home testing options while maintaining scientific rigor and user safety [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或依 賴該等內容而引致的任何損失承擔任何責任。 Mirxes Holding Company Limited （ 於 開 曼 群 島 註 冊 成 立 的 有 限 責 任 公 司 ） （股份代號：2629） 自願性公告 於泰國的近期業務發展進程 本公告乃由Mirxes Holding Company Limited（「本公司」，連同其附屬公司統稱「本 集團」）自願刊發，旨在知會本公司股東及潛在投資者有關本集團的最新業務 發展。 與N HEALTH建立戰略夥伴關係 本公司董事（「董事」）會（「董事會」）宣佈，本公司已於2025年12月15日與N Health （「N Health」，為 一 家 醫 療 保 健 解 決 方 案 供 應 商 及 泰 國 最 大 醫 療 保 健 供 應 商 Bangkok Dusit Medical Services (BDMS) Group的成員公司）建立戰略夥伴關係（「戰 略夥伴關係」）。戰略夥伴關係旨在將先進的microRN ...